The reviewers identified 11 studies comparing different mean arterial pressure strategies in septic resuscitation, including four randomized controlled trials and seven nonrandomized studies, representing 2,895 patients. When the authors pooled data from three trials reporting 90-day mortality, they observed a numerical increase in deaths with higher MAP targets: 320 of 720 patients (44.4%) versus 280 of 722 patients (38.8%). The pooled odds ratio reported was 1.31 with a 95% confidence interval of 0.97 to 1.77, a result the study team described as a nonsignificant trend toward higher mortality with elevated targets. The data as presented do not support a definitive mortality benefit from uniformly higher MAP goals in septic shock.
Shorter-term endpoints—28- or 30-day mortality—showed a similar pattern. The pooled estimate favored neither strategy decisively but again suggested a trend toward worse outcomes with higher MAP (OR 1.25, 95% CI 0.98-1.61). The authors noted that this effect remained stable in sensitivity analyses. Observational studies added heterogeneity: some cohorts linked lower MAP to greater mortality risk, while others found no significant association. The review therefore reports inconsistent mortality signals across study designs and time points rather than a clear treatment effect.
Renal endpoints were heterogeneous across studies. A subset of reports suggested that higher MAP targets might reduce the need for renal replacement therapy or improve recovery from acute kidney injury in selected populations. The review specifically calls out signals in patients with chronic hypertension and in some cirrhotic subgroups, where higher perfusion pressures appeared more favorable. The source did not provide a pooled, definitive benefit for renal outcomes, however, and other studies showed no meaningful renal advantage. The authors therefore present renal findings as inconsistent and potentially subgroup-specific rather than universally applicable.
Across trials and observational cohorts, higher MAP targets were consistently associated with increased exposure to vasopressor agents. Increased vasopressor use correlated with higher rates of arrhythmias and fewer organ support–free days in the elevated-target arms. The study team reported these harms as recurrent signals across included studies. The balance between potential organ-protective effects and increased iatrogenic harm therefore emerges as a central clinical tension in choosing MAP targets for septic resuscitation.
The review specifically aimed to evaluate splanchnic perfusion and ischemia. No included study reported splanchnic ischemia as a prespecified, discrete outcome measure. Mesenteric ischemia events were infrequent and occurred at similar rates between higher and lower MAP arms. Because splanchnic ischemia was not systematically measured or defined as a primary endpoint in the identified trials, the authors state that the evidence base cannot answer whether elevated MAP targets protect or harm splanchnic perfusion.
Risk-of-bias assessments used Cochrane RoB 2 for randomized trials and the Newcastle-Ottawa Scale for nonrandomized studies. Mortality meta-analyses used random-effects models where reported. The authors applied GRADE to evaluate overall certainty and judged the body of evidence as very low. Key contributors to low certainty included heterogeneity in study design, inconsistent direction of effect across observational reports, and sparse reporting of organ-specific outcomes such as splanchnic ischemia. The review followed PRISMA 2020 methods and synthesized nonpooled findings narratively under Synthesis Without Meta-Analysis recommendations when appropriate.
Clinicians should note that routine elevation of MAP targets above guideline-recommended goals did not demonstrate a clear mortality advantage in pooled trial data and produced consistent signals of harm—more vasopressor exposure, more arrhythmias, and fewer organ support–free days. Select patient groups, including those with chronic hypertension or cirrhosis, showed potential renal benefit in some studies; the authors therefore advocate for individualized, risk-stratified MAP targeting rather than a one-size-fits-all elevated MAP strategy.
Several unanswered questions remain and were explicitly documented by the authors. First, splanchnic ischemia was not reported as a discrete, predefined outcome in the included literature, leaving a gap in direct evidence on mesenteric perfusion. Second, renal outcome signals were inconsistent and appeared subgroup-dependent; the review did not identify definitive dosing, timing, or target thresholds that reliably confer renal protection. Third, the overall certainty of evidence was graded very low, limiting confidence in pooled estimates and subgroup findings.
Limitations the authors reported include heterogeneity across trials and observational cohorts, limited event rates for splanchnic ischemia, and variable outcome definitions across studies. The review did not invent or extrapolate additional trial details beyond what was reported; where specifics such as dosing strategies, exact vasopressor regimens, or protocolized monitoring of splanchnic perfusion were absent from the source, the authors noted those details were not reported. The practical implication from this synthesis is clear: individualized MAP goals, informed by comorbid status and organ-specific risk, warrant further rigorous evaluation in trials that prospectively measure splanchnic ischemia and prespecify renal endpoints.